Viking Therapeutics (VKTX) Operating Income (2016 - 2025)
Historic Operating Income for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to -$98.6 million.
- Viking Therapeutics' Operating Income fell 16961.65% to -$98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.8 million, marking a year-over-year decrease of 10515.5%. This contributed to the annual value of -$150.9 million for FY2024, which is 4968.31% down from last year.
- According to the latest figures from Q3 2025, Viking Therapeutics' Operating Income is -$98.6 million, which was down 16961.65% from -$74.6 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Operating Income registered a high of -$12.5 million during Q4 2021, and its lowest value of -$98.6 million during Q3 2025.
- Its 5-year average for Operating Income is -$31.9 million, with a median of -$23.7 million in 2023.
- In the last 5 years, Viking Therapeutics' Operating Income crashed by 1104.21% in 2021 and then crashed by 16961.65% in 2025.
- Quarter analysis of 5 years shows Viking Therapeutics' Operating Income stood at -$12.5 million in 2021, then plummeted by 62.13% to -$20.3 million in 2022, then tumbled by 44.38% to -$29.3 million in 2023, then plummeted by 57.89% to -$46.2 million in 2024, then plummeted by 113.16% to -$98.6 million in 2025.
- Its Operating Income stands at -$98.6 million for Q3 2025, versus -$74.6 million for Q2 2025 and -$55.5 million for Q1 2025.